Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more
Kamada (KMDA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.029x
Based on the latest financial reports, Kamada (KMDA) has a cash flow conversion efficiency ratio of 0.029x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($7.82 Million) by net assets ($269.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kamada - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Kamada's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kamada Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kamada ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Veedol Corporation Limited
NSE:VEEDOL
|
N/A |
|
Bellevue Group AG
SW:BBN
|
0.150x |
|
Fleetwood Ltd
AU:FWD
|
0.081x |
|
PDS Limited
NSE:PDSL
|
-0.080x |
|
BGF Retail Co Ltd
KO:027410
|
0.004x |
|
Dongwon System
KO:014820
|
0.072x |
|
Aurelius Technologies Bhd
KLSE:5302
|
0.070x |
|
Adcock Ingram Holdings Limited
PINK:AIHLF
|
-0.035x |
Annual Cash Flow Conversion Efficiency for Kamada (2008–2025)
The table below shows the annual cash flow conversion efficiency of Kamada from 2008 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $269.13 Million | $27.59 Million | 0.103x | -44.11% |
| 2024-12-31 | $259.46 Million | $47.59 Million | 0.183x | +937.34% |
| 2023-12-31 | $244.02 Million | $4.32 Million | 0.018x | -89.11% |
| 2022-12-31 | $176.02 Million | $28.59 Million | 0.162x | +413.24% |
| 2021-12-31 | $176.82 Million | $-9.17 Million | -0.052x | -148.48% |
| 2020-12-31 | $178.64 Million | $19.11 Million | 0.107x | -49.12% |
| 2019-12-31 | $135.32 Million | $28.44 Million | 0.210x | +123.96% |
| 2018-12-31 | $112.38 Million | $10.55 Million | 0.094x | +115.90% |
| 2017-12-31 | $89.49 Million | $3.89 Million | 0.043x | +52.93% |
| 2016-12-31 | $66.74 Million | $1.90 Million | 0.028x | +114.74% |
| 2015-12-31 | $72.51 Million | $-13.98 Million | -0.193x | -57.44% |
| 2014-12-31 | $80.99 Million | $-9.92 Million | -0.122x | -185.86% |
| 2013-12-31 | $89.97 Million | $-3.85 Million | -0.043x | +85.28% |
| 2012-12-31 | $28.39 Million | $-8.26 Million | -0.291x | -801.65% |
| 2011-12-31 | $22.67 Million | $940.36K | 0.041x | -89.67% |
| 2010-12-31 | $26.49 Million | $10.63 Million | 0.401x | +192.43% |
| 2009-12-31 | $30.15 Million | $-13.09 Million | -0.434x | +56.84% |
| 2008-12-31 | $12.64 Million | $-12.72 Million | -1.006x | -- |